Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cipla Ltd. engages in the manufacture and distribution of healthcare products and bulk drugs. It operates through the following segments: Pharmaceuticals and New Ventures. The Pharmaceuticals segment develops, manufactures, sells and distributes generic or branded generic medicines as well as active pharmaceutical ingredients. The New Ventures segment includes the operations of the two wholly owned subsidiaries, Cipla Health Ltd., a consumer healthcare company and Cipla BioTec Pvt. Ltd, which is into the business of Biosimilars. The company was founded by Khwaja Abdul Hamied in 1935 and is headquartered in Mumbai, India.

DAE HWA PHARM Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company operates through the following business divisions: Pharmaceuticals manufacturing and distribution, Pharmaceuticals Wholesale, and Pharmaceuticals Materials manufacturing and distribution. Its products include cough suppressants, expectorants, and mucolytics, drugs affecting the nervous system, drugs for liver diseases, corticosteroids, and hemorrhoid disease, analgesics, anti-inflammatory, anti-pyretics, vitamins and tonics, plaster, antihistamines, skeletal muscle relaxants, cardiovascular drugs, anti-inflammatory enzymes, gastro-intestinal drugs, iron and calcium supply, topical drugs, and injections. The company was founded by Kim Ki-Yong on January 19, 1984 and is headquartered in Hoengseong-gun, South Korea.

Ala Wai Pharma develops drug delivery systems designed to increase the effectiveness of influenza drugs. Its delivery systems focus on methodologies that target permeability and the portion of the drug activated upon entering the bloodstream, enabling patients to receive strong results from medications. The company was founded in 2011 and is headquartered in Honolulu, Hawaii.

Established in 1973 in Korea, Hanmi Pharmaceuticals now is one of the top 5 pharmaceutical companies in terms of revenue, and the most R&D focused company with the highest R&D investment for several years. Hanmi has been successful for a few decades with high flexibility, continuously changing its market/development strategy from first generics to IMD & FDC (Incrementally Modified Drug and Fixed Dose Combination) to new drug development including innovative small molecules and biologics. During the period of significant changes, Hanmi made multiple strategic collaboration relationships with multinational companies and biotech companies. Based on the success in 1980s and 1990s, Hanmi started its Chinese operation in 1996 with establishment of Beijing Hanmi. Now, Beijing Hanmi grew as a well-localized and well-settled Chinese company with more than 1,300 staffs including R&D, sales / marketing, and manufacturing experts and significant growth rate higher than 20% every year. Currently, Hanmi and Beijing Hanmi is closely collaborating on various business opportunities and new drug development projects as well as sales and marketing in Chinese territories. As the only Asian company with significant presence both in Korea and China, as the most R&D focused company with number of clinical stage projects with competitiveness, and as the company with open innovation based on multiple development/marketing collaborations, Hanmi is trying to develop and provide differentiated treatment options to patients suffering from various disease.

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.

Janghan Asset Co. Ltd. is a South Korean private company that provides investment services.

Zydus Lifesciences Ltd. engages in the discovery, development, and manufacture of pharmaceutical products under Zydus brand. The firm's products portfolio includes active pharmaceutical ingredients, human formulations, and animal health & veterinary. It operates through the following segments: Pharmaceuticals and Consumer Products. The Pharmaceuticals segment represents the business of integrated pharmaceutical operations with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products. The Consumer Products segment represents the business of development, production, marketing, and distribution of differentiated health and wellness products. The company was founded by Ramanbhai B. Patel in 1952 and is headquartered in Ahmedabad, India.

Part of Jiangsu Xiansheng Medical Diagnosis Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd. is a Chinese company located in Nanjing that manufactures and sells pharmaceutical products. The firm was founded in 1995.

GlaxoSmithKline Intellectual Property (No. 2) Ltd., a subsidiary of GSK Plc, is a company headquartered in Brentford, UK, that provides business support services. The firm was founded in 2012.\nThe company says this about itself: The Company is a member of the GlaxoSmithKline Group (the \"Group\"). The Company's principal activities are the development, enhancement, maintenance, protection and exploitation of intellectual property assets owned by the Company which may include but are not limited to, licensing out intellectual property rights relating to pharmaceutical products to the GlaxoSmithKline Group of companies and carrying out research and development activities.

Guangzhou Institutes of Biomedicine and Health (GIBH)，(simplified Chinese: 中国科学院广州生物医药与健康研究院; traditional Chinese: 中國科學院廣州生物醫藥與健康研究院; pinyin: Zhōngguó Kēxué yuan guangzhou sheng wu yi yao yu jian kang yan jiu yuan) affiliated with the Chinese Academy of Sciences, is a government-sponsored scientific research institution with independent legal jurisdiction. GIBH was established by the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government. The managerial mechanism of GIBH is the responsibility of Director-General, under the authority of the board of trustees.

Evergreen Therapeutics engages in the research and development of clinical drugs in the field of immunity and ophthalmology.

Toyama Chemical Co., Ltd. develops and supplies pharmaceutical products. It engages in information collection, clinical development of pharmaceuticals and distribution of healthcare products. The company was founded on November 15, 1936 and is headquartered in Tokyo, Japan.

Xiansheng Pharmaceutical Co., Ltd., established on 1998-09-10, The scope of business includes the production of new compound drugs or active ingredient drugs(Including raw materials and preparations);New Anticancer Drugs,Production of new cardiovascular and cerebrovascular drugs;Sell ​​self-produced products(Production and operation according to the licensing items approved by the Provincial Food and Drug Administration);road freight transport.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Zhejiang Purui Pharmaceutical Co., Ltd., established on 2009-10-29, Business scope includes licensed projects:pharmaceutical production;Technology Import and Export;Import and export(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results).General project:Manufacturing of Specialty Chemical Products(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Shanghai Fangyu Health Medicine Technology Co., Ltd., established on 2013-09-10, Business scope includes new pharmaceutical products,Health products,medical instruments,Diagnostic reagents,Research and development of pharmaceutical intermediates,and provide relevant technical advice,Technical Services,technology transfer. [Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Romark LC is a pharmaceutical company, which engages in the development and commercialization of innovative small molecules for treating infectious diseases and cancers. It markets Alinia for Oral Suspension, a drug used for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 months of age and older. The company was founded by Jean-François Rossignol and Marc S. Ayers in 1993 and is headquartered in Tampa, FL.

Biota Scientific Management Pty Ltd., a subsidiary of Vaxart, Inc., is an Australian company located in Notting Hill that develops anti-infective drugs.

Jiangsu Xiansheng Pharmaceutical Research Co., Ltd., established on 2004-02-10, Business scope includes licensed business items:No general operating items:medical products,Research on medical diagnostic reagents,Technology transfer and related technical consulting services.Self-operated and agent import and export business of various commodities and technologies.*